Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

RCANN^™ Trademark Portfolio Out-Licensed

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that its subsidiary, Akos Biosciences, has licensed to TOTEC Pharma, Inc. (“TOTEC”) its US Trademark portfolio for RCANN^™ and an RCANN^™ design. TOTEC, an affiliate of Aries Science & Technology (“Aries”), is advancing the commercialization of patented cannabinoid crème technology created by Enveric and intended for use in treatment of radiation dermatitis. The trademark license to TOTEC includes an option to purchase the RCANN trademark portfolio in the future, contingent on TOTEC meeting certain development and commercialization milestones.

“We are pleased that TOTEC has chosen to further license the RCANN trademark portfolio in connection with advancing the licensed cannabinoid technology towards commercialization,” said Joseph Tucker, PhD, CEO of Enveric. “We believe that this trademark license enhances the value to both parties of the patented cannabinoid technology previously licensed to the TOTEC affiliate, Aries, that is now being advanced by TOTEC.” Dr. Tucker added, “This license further extends the business development momentum of Enveric which has been aided by the out-licensing of non-core assets to third parties and helps build shareholder value.”

“The trademark license from Enveric helps TOTEC to position the patented cannabinoid crème technology for commercialization through a series of innovative product solutions,” said Hari Harikumar, President of TOTEC Pharma.

Dr. Tucker continued, “Enveric is supportive of the TOTEC business plan to commercialize the licensed cannabinoid crème technology and has confidence in its management and technical team. Assuming the envisioned TOTEC products are as successful as Enveric and TOTEC anticipate, the previously announced technology licensing agreement with Aries could generate significant milestone and royalties reflecting such success.”

About TOTEC Pharma

TOTEC is a privately held pharmaceutical company established to develop a focused pipeline of products based on patented cannabinoid crème technology and nano lipid–based topical delivery approaches. The company is advancing these technologies for the treatment of radiation dermatitis and other serious dermatological conditions, with an emphasis on improving skin penetration, stability, and patient experience. As an independent entity, TOTEC is dedicated to translating this specialized topical delivery science into clinically meaningful and commercially viable therapeutic products.

About Aries Science & Technology

Aries Science & Technology LLC is a materials innovation company specializing in the design and engineering of advanced encapsulation and delivery platforms for complex active ingredients. The company develops proprietary polymers, surfactants, and functional additives that create carrier systems with superior stability and controlled release of actives. Aries strengthens its materials expertise with quantitative structure–property relationship (QSPR) modeling, enabling early predictive assessments that reduce technical risk and accelerate commercialization. By integrating architected functional materials, computationally informed design, and scalable manufacturing pathways, Aries empowers partners to bring differentiated therapeutic and consumer products to market with strong competitive moats and durable intellectual property positions.

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of patent protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT₂_A and 5-HT₁_B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.

For more information, please visit www.enveric.com.

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.

A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.